Broadcast Date: 
  • Time: 

Finding a druggable target is a seemingly uncomplicated idea. Still, as the very bedrock upon which the Biotech and Pharma industries were built, it has proven to be anything but a straightforward process. The strategies for trying to identify successful lead therapeutic compounds are almost limitless, but all too often, hit detection and lead identification are met with failure as an exciting target turns out to exhibit a poor druggability profile. This can cost companies exorbitant amounts of money and, more importantly, waste valuable time, ultimately leading to fewer therapies for patients in need. Yet, what if there was a way to avoid many of the early drug discovery pitfalls?

In this GEN webinar, our distinguished speaker Dr. Benedict Cross, CTO of PhoreMost, will tell us about their screening approach called PROTEINi that “pre-discovers” the identity of new phenotypically tractable targets and their mechanisms for drug development. Dr. Cross will walk us through how the technology uses massively diverse oligo-encoded libraries to expand the druggable space available for discovery, accelerating the time taken to progress from target discovery, to hit, to lead. Additionally, we will learn how this approach is being used in various areas of the life sciences industry, such as CRISPR, protein degradation, and new clinical assets.

A live Q&A session followed the presentation, offering a chance to pose questions to our expert panelist.

Benedict Cross
Benedict Cross, PhD
Chief Technology Officer
Lina Peart
Lina Peart
Inside Sales Manager
Twist Bioscience

Twist logo